Institut Paoli-calmettes
Clinical trials sponsored by Institut Paoli-calmettes, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Blood test may predict kidney cancer drug response Results expected Dec 2026 (estimated)
- New antibody drug takes on advanced tumors in first human trial Results expected Mar 2027 (estimated)
-
Experimental combo for resistant breast cancer shows early promise but trial halted
Disease control Stopped earlyThis early-phase trial tested a combination of two oral drugs, BKM120 and lapatinib, in 24 people with HER2-positive breast cancer that had stopped responding to trastuzumab. The goal was to find a safe dose and see if the combination could shrink tumors. The study was terminated…
Phase 1/2 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Promising combo for Hard-to-Treat breast cancer hits snag, trial halted
Disease control Stopped earlyThis study tested a new drug (LY2780301) combined with standard chemotherapy (paclitaxel) in people with advanced HER2-negative breast cancer that had spread or couldn't be removed by surgery. The goal was to find the safest dose and see if the combination could shrink tumors. Th…
Phase 1/2 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Pain pump after breast surgery: hope for faster recovery?
Symptom relief Stopped earlyThis study tested whether a continuous drip of the local anesthetic ropivacaine into the surgical wound after mastectomy could improve pain control and speed up recovery. The trial planned to enroll 59 women and follow them at home after discharge. However, the study was terminat…
Phase 3 • Sponsor: Institut Paoli-Calmettes • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
New study checks immunotherapy safety in elderly cancer patients
Symptom relief Stopped earlyThis study was designed to track side effects and quality of life in people aged 70 and older with advanced melanoma or non-small cell lung cancer who are starting immunotherapy. Researchers planned to monitor 40 participants for serious side effects and changes in daily well-bei…
Phase 4 • Sponsor: Institut Paoli-Calmettes • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Scientists hunt for genetic secrets in breast cancer tumors
Knowledge-focused Stopped earlyThis study aimed to find genetic and protein changes in breast cancer that could help predict how the disease behaves. Researchers collected tumor samples from 749 adults with breast cancer and analyzed them for gene activity and mutations. The study was stopped early, so results…
Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC